The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 660
Immunogenicity of protein therapeutics
De Groot, A. S., & Scott, D. W. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.07.011 · Cited by 545
Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs
Friberg, L. E., Henningsson, A., Maas, H., Nguyen, L., & Karlsson, M. O. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.140 · Cited by 534
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1746 · Cited by 510
Clinical Pharmacokinetics of Cyclosporin
Ptachcinski, R. J., Venkataramanan, R., & Burckart, G. J. (1986) · Clinical Pharmacokinetics · doi:10.2165/00003088-198611020-00002 · Cited by 493
The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics
Fishburn, C. S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21278 · Cited by 474
A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner
Schellenberger, V., Wang, C.-W., Geething, N. C., Spink, B. J., Campbell, A., To, W., Scholle, M. D., Yin, Y., Yao, Y., Bogin, O., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1588 · Cited by 462
Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
Richter, W. F., Bhansali, S. G., & Morris, M. E. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9367-0 · Cited by 377
Therapeutic peptides: technological advances driving peptides into development
Sato, A. K., Viswanathan, M., Kent, R. B., & Wood, C. R. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.10.002 · Cited by 362
Modeling of Pharmacokinetic/Pharmacodynamic (PK/PD) Relationships: Concepts and Perspectives
Derendorf, H., & Meibohm, B. (1999) · Pharmaceutical Research · doi:10.1023/a:1011907920641 · Cited by 352
Self-citationEmerging Trends in Oral Delivery of Peptide and Protein Drugs
Mahato, R. I., Narang, A. S., Thoma, L., & Miller, D. D. (2003) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.v20.i23.30 · Cited by 352
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.suppl_3.3 · Cited by 338
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Self-citationFactors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Therapeutic application of peptides and proteins: parenteral forever?
Antosova, Z., Mackova, M., Kral, V., & Macek, T. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.07.009 · Cited by 324
Pharmacokinetic aspects of biotechnology products
Tang, L., Persky, A. M., Hochhaus, G., & Meibohm, B. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20125 · Cited by 303
Self-citationTherapeutic Strategies Based on Glucagon-Like Peptide 1
Deacon, C. F. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2181 · Cited by 296
Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin
Tuan Giam Chuang, V., Kragh-Hansen, U., & Otagiri, M. (2002) · Pharmaceutical Research · doi:10.1023/a:1015396825274 · Cited by 295
Yáñez, J. A., Remsberg, C. M., Sayre, C. L., Forrest, M. L., & Davies, N. M. (2011) · Therapeutic Delivery · doi:10.4155/tde.11.19 · Cited by 279 · cited 1×
“For a therapeutic peptide demonstrating flip-flop pharmacokinetics, the terminal half-life is prolonged following intramuscular or subcutaneous administration compared to intravenous administration because the terminal phase of the concentration–time profile is determined by the rate-limiting step, which is in this ca…”
BackgroundBasic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm, B., & Derendorf, H. (1997) · PubMed · Cited by 276
Self-citationSomatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects.
Harris, A. G. (1994) · Gut · doi:10.1136/gut.35.3_suppl.s1 · Cited by 266
Potent D-peptide inhibitors of HIV-1 entry
Welch, B. D., VanDemark, A. P., Heroux, A., Hill, C. P., & Kay, M. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708109104 · Cited by 250
Target-mediated drug disposition and dynamics
Mager, D. E. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.041 · Cited by 244
Busby, R. W., Bryant, A. P., Bartolini, W. P., Cordero, E. A., Hannig, G., Kessler, M. M., Mahajan-Miklos, S., Pierce, C. M., Solinga, R. M., Sun, L. J., et al. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.09.019 · Cited by 235
Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C
Subramanian, G. M., Fiscella, M., Lamousé-Smith, A., Zeuzem, S., & McHutchison, J. G. (2007) · Nature Biotechnology · doi:10.1038/nbt1364 · Cited by 216
Innovative approaches to anti-arrhythmic drug therapy
Nattel, S., & Carlsson, L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2112 · Cited by 209
Commercial challenges of protein drug delivery
Brown, L. R. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.1.29 · Cited by 208
Therapeutic peptides revisited
Latham, P. W. (1999) · Nature Biotechnology · doi:10.1038/11686 · Cited by 207
Improving the therapeutic efficacy of peptides and proteins: A role for polysialic acids
Gregoriadis, G., Jain, S., Papaioannou, I., & Laing, P. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.06.007 · Cited by 202
Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., & for the Albiglutide Study Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1518 · Cited by 198
Population pharmacokinetic studies in pediatrics: Issues in design and analysis
Meibohm, B., Läer, S., Panetta, J. C., & Barrett, J. S. (2005) · The AAPS Journal · doi:10.1208/aapsj070248 · Cited by 187
Self-citationPast, Present, and Future Technologies for Oral Delivery of Therapeutic Proteins
Singh, R., Singh, S., & Lillard, J. W. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21183 · Cited by 186 · cited 2×
“Without this minimum degree of lipophilicity, there is no passive transcellular permeation, whereas the alternative paracellular pathway is restricted to small compounds less than 200 Da [16].”
BackgroundPhysiologically Based Pharmacokinetic (PBPK) Modeling in Children
Barrett, J. S., Della Casa Alberighi, O., Läer, S., & Meibohm, B. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.64 · Cited by 182
Self-citationA stapled BIM peptide overcomes apoptotic resistance in hematologic cancers
LaBelle, J. L., Katz, S. G., Bird, G. H., Gavathiotis, E., Stewart, M. L., Lawrence, C., Fisher, J. K., Godes, M., Pitter, K., Kung, A. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci46231 · Cited by 176
The LHRH antagonist Cetrorelix: a review
Reissmann, T. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.4.322 · Cited by 172
Clinical Pharmacokinetics of Depot Leuprorelin
Periti, P., Mazzei, T., & Mini, E. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00003 · Cited by 170
Stanley, T. L., Chen, C. Y., Branch, K. L., Makimura, H., & Grinspoon, S. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1587 · Cited by 163
Design of a Potent d-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance
Welch, B. D., Francis, J. N., Redman, J. S., Paul, S., Weinstock, M. T., Reeves, J. D., Lie, Y. S., Whitby, F. G., Eckert, D. M., Hill, C. P., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01339-10 · Cited by 159
Pharmacokinetic/Pharmacodynamic Studies in Drug Product Development
Meibohm, B., & Derendorf, H. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.1167 · Cited by 159
Self-citationFerdinandi, E. S., Brazeau, P., High, K. A., Procter, B. G., Fennell, S., & Dubreuil, P. (2006) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00008.x · Cited by 153
Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Lin, J. H. (2009) · Current Drug Metabolism · doi:10.2174/138920009789895499 · Cited by 153
Binkley, N., Bolognese, M., Sidorowicz-Bialynicka, A., Vally, T., Trout, R., Miller, C., Buben, C. E., Gilligan, J. P., Krause, D. S., & for the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1602 · Cited by 149 · cited 1×
“Oral calcitonin is currently in phase III clinical trials for the treatment of osteoporosis or osteoarthritis [21].”
BackgroundCharacterizing the Impact of Renal Impairment on the Clinical Pharmacology of Biologics
Meibohm, B., & Zhou, H. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011413894 · Cited by 146
Self-citationAgoram, B. M., Martin, S. W., & van der Graaf, P. H. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.002 · Cited by 146
Monomeric Fc Fusions: Impact on Pharmacokinetic and Biological Activity of Protein Therapeutics
Dumont, J. A., Low, S. C., Peters, R., & Bitonti, A. J. (2006) · BioDrugs · doi:10.2165/00063030-200620030-00002 · Cited by 145
Baggio, L. L., Huang, Q., Cao, X., & Drucker, D. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.017 · Cited by 137
Zhao, L. Y., Ji, P., Li, Z., Roy, P., & Sahajwalla, C. G. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.4 · Cited by 128
Vickers, A. E. M., Fischer, V., Connors, S., Fisher, R. L., Baldeck, J. P., Maurer, G., & Brendel, K. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08798-7 · Cited by 126
Lymphatic transport of proteins after s.c. injection: implications of animal model selection
Porter, C. J. H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00153-3 · Cited by 123
Rosenstock, J., Balas, B., Charbonnel, B. H., Bolli, G. B., Boldrin, M. N., Ratner, R. E., Balena, R., & for the T-emerge 2 Study Group (2012) · Diabetes Care · doi:10.2337/dc12-0709 · Cited by 119
Delivery of Bioactive Peptides and Proteins Across Oral (Buccal) Mucosa
Senel, S., Kremer, M. J., Katalin, N., & Squier, C. A. (2001) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201013378734 · Cited by 119
Ipamorelin, the first selective growth hormone secretagogue
Raun, K., Hansen, B. S., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390552 · Cited by 102
Concepts and Challenges in Quantitative Pharmacology and Model-Based Drug Development
Zhang, L., Pfister, M., & Meibohm, B. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9062-3 · Cited by 95
Self-citationPharmacokinetics of Gonadotropin-Releasing Hormone and Its Analogs
Handelsman, D. J., & Swerdloff, R. S. (1986) · Endocrine Reviews · doi:10.1210/edrv-7-1-95 · Cited by 95
Karsdal, M. A., Henriksen, K., Bay‐Jensen, A., Molloy, B., Arnold, M., John, M. R., Byrjalsen, I., Azria, M., Riis, B. J., Qvist, P., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010372625 · Cited by 91
Wang, Y., Krzyżański, W., Doshi, S., Xiao, J. J., Ruixo, J. J. P., & Chow, A. T. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9234-9 · Cited by 83
Läer, S., Barrett, J. S., & Meibohm, B. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337513 · Cited by 75
Self-citationLoRusso, P. M., Venkatakrishnan, K., Ramanathan, R. K., Sarantopoulos, J., Mulkerin, D. L., Shibata, S., Hamilton, A. L., Dowlati, A., Mani, S., Rudek, M. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2873 · Cited by 71
Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative
Agersø, H., & Vicini, P. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00073-3 · Cited by 66
Chemically programmed antibodies: Endothelin receptor targeting CovX-Bodies™
Doppalapudi, V. R., Tryder, N., Li, L., Aja, T., Griffith, D. A., Liao, F., Roxas, G., Ramprasad, M. P., Bradshaw, C. W., & Barbas, C. F. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.10.009 · Cited by 59
A mathematical model of the human menstrual cycle for the administration of GnRH analogues
Röblitz, S., Stötzel, C., Deuflhard, P., Jones, H. M., Azulay, D.-O., van der Graaf, P. H., & Martin, S. W. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2012.11.020 · Cited by 54
Pharmacokinetics and Pharmacodynamics of Biotech Drugs
Meibohm, B., & Derendorf, H. (2006) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.200400105 · Cited by 47
Self-citationde Serres, M., Ellis, B., Dillberger, J. E., Rudolph, S. K., Hutchins, J. T., Boytos, C. M., Weigl, D., & DePrince, R. B. (1999) · Stem Cells · doi:10.1002/stem.170203 · Cited by 46
Verschraegen, C. F., Westphalen, S., Hu, W., Loyer, E. M., Kudelka, A. P., Völker, P., Kavanagh, J. J., Steger, M., Schulz, K.-D., & Emons, G. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00408-6 · Cited by 43
Guzmán, C. A., & Feuerstein, G. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1132-2 · Cited by 43
Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
Gao, W., & Jusko, W. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175752 · Cited by 41
Immunogenicity in Peptide-Immunotherapy: From Self/Nonself to Similar/Dissimilar Sequences
Kanduc, D. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-09789-3_15 · Cited by 40
Ruixo, J. J. P., Krzyżański, W., Bouman‐Thio, E., Miller, B. H., Jang, H., Bai, S. A., Zhou, H., Yohrling, J., Cohen, A. F., Burggraaf, J., et al. (2009) · Clinical Pharmacokinetics · doi:10.2165/11317190-000000000-00000 · Cited by 40
Wang, Y., Sloey, B., Wong, T., Khandelwal, P., Melara, R., & Sun, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0420-y · Cited by 40
Physiologically-Based PK/PD Modelling of Therapeutic Macromolecules
Thygesen, P., Macheras, P. E., & Peer, A. V. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9990-3 · Cited by 36
Samtani, M. N., Ruixo, J. J. P., Brown, K. H., Cerneus, D. P., & Molloy, C. J. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008329559 · Cited by 36
Nagaraja, N., Pechstein, B., Erb, K., Klipping, C., Hermann, R., Niebch, G., & Derendorf, H. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.111481 · Cited by 31
Giannoukakis, N. (2003) · PubMed · Cited by 30
Gobburu, J. V. S., Agersø, H., Jusko, W. J., & Ynddal, L. (1999) · Pharmaceutical Research · doi:10.1023/a:1018955126402 · Cited by 28
Jadhav, P. R., Agersø, H., Tornøe, C. W., & Gobburu, J. V. S. (2006) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-006-9025-1 · Cited by 27
Stapled peptide to enter human testing, but affinity questions remain
Grigoryev, Y. A. (2013) · Nature Medicine · doi:10.1038/nm0213-120a · Cited by 24
Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance
Welch, B. D., Francis, J. N., Redman, J. S., Paul, S., Weinstock, M. T., Reeves, J. D., Lie, Y., Whitby, F. G., Eckert, D. M., Hill, C. P., et al. (2013) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 24
Exenatide: A Novel Incretin Mimetic Agent for Treating Type 2 Diabetes Mellitus
Lam, S., & See, S. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000223655.16253.e4 · Cited by 22
Herédi‐Szabó, K., Murphy, R. F., & Lovas, S. (2006) · Journal of Peptide Science · doi:10.1002/psc.783 · Cited by 14
Frank, T. (2013) · Journal of Pharmaceutics & Drug Delivery Research · doi:10.4172/2325-9604.1000112 · Cited by 14
Comparison of the immunogenicity of wasp venom peptides with or without carbohydrate moieties
Ho, C. L., Lin, Y.-L., Chen, W.-C., Rocchi, R., & Piek, T. (1998) · Toxicon · doi:10.1016/s0041-0101(97)00066-4 · Cited by 8
Cited by
Therapeutic Peptides: Current Applications and Future Directions
Wang, L., Wang, N., Zhang, W., Cheng, X., Yan, Z., Shao, G., Wang, X., Wang, R., & Fu, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00904-4 · Cited by 2,131
The Current State of Peptide Drug Discovery: Back to the Future?
Henninot, A., Collins, J. C., & Nuss, J. M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00318 · Cited by 1,113
Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges
Vinogradov, A. A., Yin, Y., & Suga, H. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b13178 · Cited by 848
Strategic Approaches to Optimizing Peptide ADME Properties
Di, L. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9687-3 · Cited by 669
“Examples of oral peptides in development include calcitonin in phase III, glucagon-like peptide-1 (GLP-1), and parathyroid hormone in phase I (5,12,15).”
BackgroundInfluentialFusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
Strohl, W. R. (2015) · BioDrugs · doi:10.1007/s40259-015-0133-6 · Cited by 461
Metadata
- Authors
- Diao, L., & Meibohm, B.
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-05-30
- Volume
- 52
- Issue
- 10
- Pages
- 855-868
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2012987104
- Cited by
- 369
- References
- 85
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.